Drug Discovery & Development | EU Committee Backs Roche Leukemia Drug Combo Drug Discovery & Development ... without their disease worsening (progression free survival; PFS) compared to chlorambucil alone and compared to MabThera (rituximab) plus chlorambucil while also increasing the depth of remissions as measured by Minimal Residual Disease (MRD). |
